RPI MN

Drug Profile

RPI MN

Alternative Names: pepteron; RPI-MN

Latest Information Update: 14 Dec 2015

Price : $50

At a glance

  • Originator ReceptoPharm
  • Developer Bio Therapeutics; ReceptoPharm
  • Class Antiretrovirals; Cobra neurotoxin proteins
  • Mechanism of Action Nicotinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Amyotrophic lateral sclerosis; Herpes simplex virus infections; HIV infections
  • Discontinued Rabies; Viral infections

Most Recent Events

  • 14 Dec 2015 Phase-I clinical trials in Herpes simplex virus infections in USA (Parenteral)
  • 14 Dec 2015 Phase-I clinical trials in Amyotrophic lateral sclerosis in USA (Parenteral)
  • 14 Dec 2015 Phase-I clinical trials in HIV infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top